Hospitalization rates in patients during long-term treatment with long-acting risperidone injection

Journal of Applied Research

Volumn 5, Issue 2, 2005, Pages 266-274

  Chue, Pierre ^a   Llorca, Pierre Michel ^b   Duchesne, Inge ^c   Leal, Adriane ^d   Rosillon, Dominique ^d   Mehnert, Angelika ^c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b SERVICE DE RHUMATOLOGIE   (France)

^c Janssen Pharmaceutica NV   (Belgium)

^d SGS Medisearch International NV   (Belgium)

Author keywords

Atypical antipsychotics; Long acting risperidone injection; Re hospitalization; Relapse; Schizophrenia

Indexed keywords

AGENTS ACTING ON THE EYE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; MUSCLE RELAXANT AGENT; NEUROLEPTIC AGENT; RISPERIDONE; SEDATIVE AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FEMALE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; RELAPSE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 21844440785     PISSN: 1537064X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56:241-247.
2. Watt DC, Katz K, Shepherd M. The natural history of schizophrenia: a 5-year prospective follow-up of a representative sample of schizophrenics by means of a standardized clinical and social assessment. Psychol Med. 1983;13:663-670.
3. Lieberman JA, Koreen AR, Chakos M, et al. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry. 1996;57(suppl 9):5-9.
4. Misdrahi D, Llorca PM, Lancon C, Bayle FJ. Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications. [French] Encephale. 2002;28:266-272.
5. Davies LM, Drummond MF. Economics and schizophrenia: the real cost. Br J Psychiatry. 1994;25(suppl):18-21.
6. Almond S, O'Donnell O. Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol. Pharmacoeconomics. 2000;17:383-389.
7. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull. 1995;21:419-429.
8. Goeree R, O'Brien BJ, Goering P, et al. The economic burden of schizophrenia in Canada. Can J Psychiatry. 1999;44:46-72.
9. Hogarty GE, Schooler NR, Ulrich R, Mussare F, Ferro P, Herron E. Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry. 1979;36:1283-1294.
10. Hogarty GE. Ulrich RF. The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. J Psychiatr Res. 1998;32:243-250.
11. Adams CE, Fenton MK, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry. 2001;179:290-299.
12. Davis JM, Kane JM, Marder SR, et al. Dose response of prophylactic antipsychotics. J Clin Psychiatry. 1993;54(suppl):24-30.
13. Remington GJ, Adams ME. Depot neuroleptic therapy: clinical considerations. Can J Psychiatry. 1995;40:S5-S11.
14. Barnes TR, Curson DA. Long-term depot antipsychotics. A risk-benefit assessment. Drug Saf. 1994;10:464-479.
15. Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC. Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial. II. The incidence of compliance problems, side-effects, neurotic symptoms and depression. Br J Psychiatry. 1985;146:469-474.
16. Tuninger E, Levander S. Long-term outcome of depot neuroleptic maintenance treatment among chronic psychotic patients. Acta Psychiatr Scand. 1997;96:347-353.
17. Bristow MF, Hirsch SR. Pitfalls and problems of the long term use of neuroleptic drugs in schizophrenia. Drug Saf. 1993;8:136-148.
18. Simpson GM, Lindenmayer JP Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol. 1997;17:194-201.
19. Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res. 2000;43:135-145.
20. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med. 2002;346:16-22.
21. Love RC, Conley RR, Kelly DL, Bartko JJ. A comparison of rehospitalization rates between patients treated with atypical antipsychotics and those treated with depot antipsychotics. Schizophr Res. 1999;36:345.
22. Moore DB, Kelly DL, Sherr JD, Love RC, Conley RR. Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone. Am J Health Syst Pharm. 1998;55:S17-S19.
23. Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second generation antipsychotic. J Clin Psychiatry. 2003;64:1250-1257.
24. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003;160:1125-1132.
25. APA. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
26. Dellva MA, Tran P, Tollefson GD, Wentley AL, Beasley CM Jr. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. Psychiatr Serv. 1997;48:1571-1577.
27. Tran PV, Dellva MA, Tollefson GD, Wentley AL, Beasley CM Jr. Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br J Psychiatry. 1998;172:499-505.
28. Weiden P, Aquila R, Standard J. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry. 1996;57(suppl 11):53-60.
29. Fahrmeir L, Tutz G. Multivariate Statistical Modelling Based on Generalized Linear Models. 2nd ed. New York, NY: Springer; 2001.
30. Stokes MA, Davis C, Koch GG. Categorical Data Analysis Using the SAS System. Cary, NC: SAS Institute Inc; 1995.
31. Rabinowitz J, Lichtenberg P, Kaplan Z, Mark M, Nahon D, Davidson M. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry. 2001;158:266-269.
32. Conley RR, Love RC, Kelly DL, Bartko JJ. Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. Am J Psychiatry. 1999;156:863-868.
33. Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55(8): 886-91.